EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Alba A BrandesMartin J van den Bent


Glioblastoma is a highly vascularised tumour with a high expression of both vascular endothelial growth factor (VEGF) and VEGFR. PTK787/ZK222584 (PTK/ZK, vatalanib), a multiple VEGF receptor inhibitor, blocks the intracellular tyrosine kinase activity of all known VEGF receptors and is therefore suitable for long-term therapy of pathologic tumour neovascularisation. The study was designed as an open-label, phase I/II study. A classic 3+3 design was selected. PTK/ZK was added to standard concomitant and adjuvant treatment, beginning in the morning of day 1 of radiotherapy (RT), and given continuously until disease progression or toxicity. PTK/ZK doses started from 500 mg with subsequent escalations to 1000 and 1250 mg/d. Adjuvant or maintenance PTK after the end of radiochemotherapy was given at a previously established dose of 750 mg twice daily continuously with TMZ at the standard adjuvant dose. Twenty patients were enrolled. Dose-limiting toxicities at a once daily dose of 1250 mg were grade 3 diarrhoea (n=1), grade 3 ALT increase (n=2), and myelosuppression with grade 4 thrombocytopenia and neutropenia (n=1). The recommended dose of PTK/ZK in combination with radiotherapy and temozolomide (TMZ) is 1000 mg once a day. This t...Continue Reading


Jun 2, 2004·International Journal of Cancer. Journal International Du Cancer·Anastasia ParthymouEvangelia Papadimitriou
Oct 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James J VredenburghHenry S Friedman


Feb 19, 2013·Current Treatment Options in Neurology·Jennie W Taylor, Elizabeth R Gerstner
Oct 14, 2011·Future Oncology·Mersiha HadziahmetovicArnab Chakravarti
Feb 11, 2014·Current Oncology Reports·Mohamed Ali Hamza, Mark R Gilbert
Apr 29, 2014·Clinical Oncology : a Journal of the Royal College of Radiologists·M AjazA Chalmers
May 16, 2014·Neuro-oncology·Roger Stupp, Michael Weller
Sep 1, 2014·Current Treatment Options in Oncology·Alissa A Thomas, Antonio Omuro
Sep 16, 2014·Seminars in Radiation Oncology·Jennifer L Clarke
Jun 1, 2012·Expert Opinion on Drug Discovery·Terreia S Jones, Eric C Holland
Feb 27, 2015·International Journal of Cancer. Journal International Du Cancer·Andreas K A GaumannGeorg Breier
Mar 27, 2015·Neoplasia : an International Journal for Oncology Research·Hongxiang WangJuxiang Chen
Jun 7, 2011·Critical Reviews in Oncology/hematology·Arend H SikkemaEveline S J M de Bont
Mar 18, 2011·Trends in Molecular Medicine·Ren-Yuan BaiGregory J Riggins
Sep 22, 2010·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Giuseppe MinnitiRiccardo Maurizi Enrici
Aug 17, 2010·Neuroimaging Clinics of North America·Eudocia C Quant, Patrick Y Wen
Jun 16, 2010·Pharmacology & Therapeutics·Leopold ArkoJohn K Park
Jun 5, 2014·Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine·Felix RaschkeFranklyn A Howe
Dec 3, 2013·Autoimmune Diseases·Norma Y Hernández-PedroJulio Sotelo
May 7, 2015·Pharmacology & Therapeutics·Constantinos Alifieris, Dimitrios T Trafalis
Mar 8, 2014·Clinical Oncology : a Journal of the Royal College of Radiologists·E J SearleI J Stratford
Apr 10, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Anne DucassouElizabeth Cohen-Jonathan Moyal
Jul 15, 2016·Journal of Medicinal Chemistry·Timothy P Heffron
Feb 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christine Lu-EmersonRakesh K Jain
Jun 22, 2011·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Zhi-Xing CaoYing-Lan Zhao
Feb 23, 2019·Neurologia Medico-chirurgica·Takanori NozawaAkiyoshi Kakita
Apr 29, 2010·Current Oncology Reports·Mustafa Khasraw, Andrew B Lassman
Jun 30, 2009·Journal of Neuro-oncology·Andrew D NordenPatrick Y Wen
May 19, 2012·Expert Review of Anticancer Therapy·Mairéad G McNamara, Warren P Mason
Jun 10, 2014·International Journal of Speech-language Pathology·Ann NordbergAnette Lohmander
Nov 18, 2010·Expert Review of Anticancer Therapy·Rafael RoeslerGilberto Schwartsmann
Sep 28, 2010·Journal of Neuro-oncology·B NeynsJ De Greve
Jul 26, 2016·Molecular and Clinical Oncology·Xiaofeng ZhouQichun Wei
Nov 16, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tracy T BatchelorMichael Weller

Related Concepts

ZK 222584
Antineoplastic Chemotherapy Protocols
Brain Tumor, Recurrent
Glioblastoma Multiforme
Chemotherapy, Adjuvant
Radiotherapy, Adjuvant

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Related Papers

The New England Journal of Medicine
Roger StuppNational Cancer Institute of Canada Clinical Trials Group
International Journal of Radiation Oncology, Biology, Physics
Jan DrappatzPatrick Y Wen
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Teri N KreislHoward A Fine
The New England Journal of Medicine
Charles E GeyerDavid Cameron
© 2021 Meta ULC. All rights reserved